Correction: Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma

doi:10.1158/1078-0432.ccr-17-2858

Correction: Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-17-2858 ◽

2018 ◽

Vol 24 (2) ◽

pp. 500-501

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Combination Therapy ◽

Mek Inhibitor ◽

Advanced Soft Tissue Sarcoma ◽

Safety And Efficacy ◽

Phase Ib ◽

Vegf Inhibitor ◽

Correction Phase

Download Full-text

Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-17-0272 ◽

2017 ◽

Vol 23 (15) ◽

pp. 4027-4034 ◽

Cited By ~ 20

Author(s):

Vivek Subbiah ◽

Christian Meyer ◽

Ralph Zinner ◽

Funda Meric-Bernstam ◽

Marianna L. Zahurak ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Combination Therapy ◽

Mek Inhibitor ◽

Advanced Soft Tissue Sarcoma ◽

Safety And Efficacy ◽

Phase Ib ◽

Vegf Inhibitor

Download Full-text

A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.10501 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 10501-10501 ◽

Cited By ~ 14

Author(s):

William D. Tap ◽

Robin L Jones ◽

Bartosz Chmielowski ◽

Anthony D. Elias ◽

Douglas Adkins ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Platelet Derived Growth Factor ◽

Advanced Soft Tissue Sarcoma ◽

Safety And Efficacy ◽

Phase Ib ◽

Factor Α

Download Full-text

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.10514 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 10514-10514 ◽

Cited By ~ 2

Author(s):

Steven Attia ◽

Richard F. Riedel ◽

Steven Ian Robinson ◽

Robert Martin Conry ◽

Kamalesh Kumar Sankhala ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Dose Escalation ◽

Advanced Soft Tissue Sarcoma ◽

Dose Escalation Study ◽

Phase Ib

Download Full-text

510P Safety and efficacy of eribulin mesylate in patients with advanced soft tissue sarcoma in daily practice

Annals of Oncology ◽

10.1016/s0923-7534(21)00668-2 ◽

2016 ◽

Vol 27 ◽

pp. ix165-ix166

Author(s):

C. Inagaki ◽

T. Shimoi ◽

H.S. Okuma ◽

A. Kawachi ◽

A. Shimomura ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Daily Practice ◽

Advanced Soft Tissue Sarcoma ◽

Eribulin Mesylate ◽

Safety And Efficacy

Download Full-text

A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti–platelet-derived growth factor &agr; (pdgfr&agr;) monoclonal antibody, in advanced soft tissue sarcoma (sts)

Annals of Oncology ◽

10.1093/annonc/mdw343.01 ◽

2016 ◽

Vol 27 ◽

pp. iv98 ◽

Cited By ~ 2

Author(s):

W. Tap ◽

R.L. Jones ◽

B. Chmielowski ◽

A.D. Elias ◽

D. Adkins ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Platelet Derived Growth Factor ◽

Advanced Soft Tissue Sarcoma ◽

Safety And Efficacy ◽

Phase 1B

Download Full-text

510P Safety and efficacy of eribulin mesylate in patients with advanced soft tissue sarcoma in daily practice

Annals of Oncology ◽

10.1093/annonc/mdw597.010 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Author(s):

C. Inagaki ◽

T. Shimoi ◽

H.S. Okuma ◽

A. Kawachi ◽

A. Shimomura ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Daily Practice ◽

Advanced Soft Tissue Sarcoma ◽

Eribulin Mesylate ◽

Safety And Efficacy

Download Full-text

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30507-1 ◽

2016 ◽

Vol 17 (12) ◽

pp. 1732-1742 ◽

Cited By ~ 100

Author(s):

Olivier Mir ◽

Thomas Brodowicz ◽

Antoine Italiano ◽

Jennifer Wallet ◽

Jean-Yves Blay ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase 2 ◽

Advanced Soft Tissue Sarcoma ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial

Download Full-text

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

BMC Cancer ◽

10.1186/s12885-019-5988-3 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 6

Author(s):

Axel Le Cesne ◽

Sebastian Bauer ◽

George D. Demetri ◽

Guangyang Han ◽

Luca Dezzani ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Advanced Soft Tissue Sarcoma ◽

Safety And Efficacy ◽

Subgroup Analyses

Download Full-text

Faculty Opinions recommendation of Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726858212.793552149 ◽

2018 ◽

Author(s):

Richard Riedel

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase 2 ◽

Advanced Soft Tissue Sarcoma ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial

Download Full-text

Abstract B279: A phase I study determining the safety and tolerability of combination therapy with Pazopanib (P), a VEGFR/PDGFR/Raf inhibitor, and GSK1120212 (Trametinib: T), a MEK inhibitor, in advanced solid tumors with expansion cohorts in advanced differentiated thyroid cancer (DTC), cholangiocarcinoma (ChCA), and soft tissue sarcoma (STS).

10.1158/1535-7163.targ-13-b279 ◽

2013 ◽

Cited By ~ 2

Author(s):

Nilofer Azad ◽

Douglas Ball ◽

Steven Sherman ◽

Michelle Rudek ◽

Gerald Falchook ◽

...

Keyword(s):

Thyroid Cancer ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Combination Therapy ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Differentiated Thyroid Cancer ◽

Mek Inhibitor ◽

Advanced Solid Tumors

Download Full-text